Synthesis of Block Copolymers to Deliver Ortho-Carborane for Proton Capture Therapy

https://openworks.mdanderson.org/sumexp22/1103/thumbnail.jp

An update and reassessment of vascular plant species richness and distribution in Bach Ma National Park, Central Vietnam

Bach Ma National Park (BMNP) is recognized as an essential biodiversity hotspot in Vietnam because of its diverse topography, high species richness and threatened and endemic species. This study updates the richness and distribution of vascular plant species in the BMNP by intergrading data from literature, field surveys, key-informant interviews and participatory observations. Our results showed that the park has a high diversity of vascular plants with 1,874 species belonging to 192 families, 6 phylums including Psilotophyta, Lycopodiophyta, Equisetophyta, Polypodiophyta, Pinophyta, and Magnoliophyta. It also indicates that 199 out of 1,874 vascular species in the BMNP are listed as endangered, precious and rare plant species of Vietnam. In particular, 55 species are part of the IUCN 2020 list, in which 9 are critically endangered species (CR), 15 are endangered species (EN), and 31 are vulnerable species (VU). According to the rankings of the Red List Vietnam (2007), 6 species of CR (accounting for 13.64% compared with the whole country), 36 species of EN (20%), and 52 species of VU (26%) were found in this area. The results provided that vascular plant species are distributed into 2 types based on high altitude (threshold at 900m), but there are no dominant communities. The findings may be essential information for foresters and biologists to recognize and use it as the newest update for their next scientific research in conservation and resource management.Vườn Quốc gia (VQG) Bạch Mã được xem là một điểm nóng đa dạng sinh học quan trọng ở Việt Nam vì địa hình đa dạng, độ phong phú loài cao, đặc biệt là các loài đặc hữu và nguy cấp. Trong nghiên cứu này, chúng tôi đã cập nhật sự phong phú và phân bố của các loài thực vật bậc cao tại VQG Bạch Mã bằng cách kết hợp dữ liệu từ tổng quan tài liệu, khảo sát thực địa, phỏng vấn người am hiểu và điều tra có sự tham gia. Kết quả cho thấy VQG có hệ thực vật bậc cao phong phú với 1.874 loài, thuộc 192 họ, 6 ngành bao gồm Psilotophyta, Lycopodiophyta, Equisetophyta, Polypodiophyta, Pinophyta, Magnoliophyta. Kết quả chỉ ra rằng 199 trong số 1.874 loài thực vật bậc cao tại VQG này được xếp vào danh sách các loài nguy cấp của Việt Nam. Đặc biệt, có 55 loài thuộc danh mục của IUCN năm 2020, trong đó có 9 loài Cực kỳ nguy cấp (CR), 15 loài Nguy cấp (EN) và 31 loài Sẽ nguy cấp (VU). Trong khi đó, theo xếp hạng của Sách Đỏ Việt Nam (2007), nghiên cứu cho thấy có 6 loài CR (chiếm 13,64% so với cả nước), 36 loài EN (20%) và 52 loài VU (26%). Phát hiện của chúng tôi cũng chỉ ra rằng đặc điểm phân bố của các loài thực vật bậc cao ở VQG Bạch Mã gồm 2 kiểu rừng dựa trên độ cao (mức 900m), nhưng không có quần xã nào chiếm ưu thế. Các kết quả này được kỳ vọng sẽ là nguồn thông tin cần thiết cho các nhà hoạt động lâm nghiệp và sinh vật học sử dụng nó như một bản cập nhật mới nhất cho các nghiên cứu khoa học tiếp theo trong bảo tồn và quản lý tài nguyên

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Portable and non-invasive blood glucose monitoring over a prolonged period using whispering gallery modes at 2.4 GHz

Invasive measurement of blood glucose is not appropriate for everyone, particularly the patients with leukemia. Here, we demonstrate how the blood glucose can be non-invasively monitored over a prolonged period in the absence of any expensive equipment. Method: A portable and non-invasive glucose sensor capable of monitoring blood glucose at real-time has been successfully constructed and tested in the absence of any vector network analyzer. Using vacuum suction, the sensor head of the proposed non-invasive glucose sensor forms a whispering gallery resonator out of a skin tissue on an arm during the measurement process. The architecture of the proposed glucose sensor is equipped with standard components, including a WiFi transmitter, an RSSI sensor and a microcontroller based computer display. Results: Using the proposed glucose sensor, a healthy volunteer has been his blood glucose levels monitored over 72 minutes after consuming a loaf of bread and a cup of cow milk. The measured blood glucose rose shortly after the meal until it peaked at 40 minutes and finally fell to the initial value at around 72 minutes. Conclusion: The overall results were in general consistent with the expected results. The proposed glucose sensor is expected to be instrumental for the individuals who dislike the traditional lancets

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921